Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

239 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.
Mascarenhas J, Hoffman R, Talpaz M, Gerds AT, Stein B, Gupta V, Szoke A, Drummond M, Pristupa A, Granston T, Daly R, Al-Fayoumi S, Callahan JA, Singer JW, Gotlib J, Jamieson C, Harrison C, Mesa R, Verstovsek S. Mascarenhas J, et al. Among authors: szoke a. JAMA Oncol. 2018 May 1;4(5):652-659. doi: 10.1001/jamaoncol.2017.5818. JAMA Oncol. 2018. PMID: 29522138 Free PMC article. Clinical Trial.
Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial.
Mesa RA, Vannucchi AM, Mead A, Egyed M, Szoke A, Suvorov A, Jakucs J, Perkins A, Prasad R, Mayer J, Demeter J, Ganly P, Singer JW, Zhou H, Dean JP, Te Boekhorst PA, Nangalia J, Kiladjian JJ, Harrison CN. Mesa RA, et al. Among authors: szoke a. Lancet Haematol. 2017 May;4(5):e225-e236. doi: 10.1016/S2352-3026(17)30027-3. Epub 2017 Mar 20. Lancet Haematol. 2017. PMID: 28336242 Free PMC article. Clinical Trial.
Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Munir T, Brown JR, O'Brien S, Barrientos JC, Barr PM, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Kipps TJ, Moreno C, Montillo M, Burger JA, Byrd JC, Hillmen P, Dai S, Szoke A, Dean JP, Woyach JA. Munir T, et al. Among authors: szoke a. Am J Hematol. 2019 Dec;94(12):1353-1363. doi: 10.1002/ajh.25638. Epub 2019 Oct 13. Am J Hematol. 2019. PMID: 31512258 Free PMC article. Clinical Trial.
Characterization of low-grade arthralgia, myalgia, and musculoskeletal pain with ibrutinib therapy: pooled analysis of clinical trials in patients with chronic lymphocytic leukemia and mantle cell lymphoma.
Siddiqi T, Coutre S, McKinney M, Barr PM, Rogers K, Mokatrin A, Valentino R, Szoke A, Deshpande S, Zhu A, Arango-Hisijara I, Osei-Bonsu K, Wang M, O'Brien S. Siddiqi T, et al. Among authors: szoke a. Leuk Lymphoma. 2022 Jul;63(7):1580-1588. doi: 10.1080/10428194.2022.2038372. Epub 2022 Feb 28. Leuk Lymphoma. 2022. PMID: 35227147 Clinical Trial.
Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia.
Barr PM, Owen C, Robak T, Tedeschi A, Bairey O, Burger JA, Hillmen P, Coutre SE, Dearden C, Grosicki S, McCarthy H, Li JY, Offner F, Moreno C, Zhou C, Hsu E, Szoke A, Kipps TJ, Ghia P. Barr PM, et al. Among authors: szoke a. Blood Adv. 2022 Jun 14;6(11):3440-3450. doi: 10.1182/bloodadvances.2021006434. Blood Adv. 2022. PMID: 35377947 Free PMC article. Clinical Trial.
Quantitative assessment of JAK2 V617F and CALR mutations in Philadelphia negative myeloproliferative neoplasms.
Gángó A, Mózes R, Boha Z, Kajtár B, Timár B, Király PA, Kiss R, Fésüs V, Nagy N, Demeter J, Körösmezey G, Borbényi Z, Marton I, Szőke A, Masszi T, Farkas P, Várkonyi J, Plander M, Pósfai É, Egyed M, Pál K, Radványi G, Hamed A, Csomor J, Matolcsy A, Alpár D, Bödör C. Gángó A, et al. Among authors: szoke a. Leuk Res. 2018 Feb;65:42-48. doi: 10.1016/j.leukres.2017.12.005. Epub 2018 Jan 2. Leuk Res. 2018. PMID: 29306106
Familial Acute Myeloid Leukemia and Myelodysplasia in Hungary.
Király AP, Kállay K, Gángó A, Kellner Á, Egyed M, Szőke A, Kiss R, Vályi-Nagy I, Csomor J, Matolcsy A, Bödör C. Király AP, et al. Among authors: szoke a. Pathol Oncol Res. 2018 Jan;24(1):83-88. doi: 10.1007/s12253-017-0216-4. Epub 2017 Mar 29. Pathol Oncol Res. 2018. PMID: 28357685 Free article.
Stroke in essential thrombocythemia.
Pósfai É, Marton I, Szőke A, Borbényi Z, Vécsei L, Csomor A, Sas K. Pósfai É, et al. Among authors: szoke a. J Neurol Sci. 2014 Jan 15;336(1-2):260-2. doi: 10.1016/j.jns.2013.10.016. Epub 2013 Oct 16. J Neurol Sci. 2014. PMID: 24183283
The impact of schizophrenia genetic load and heavy cannabis use on the risk of psychotic disorder in the EU-GEI case-control and UK Biobank studies.
Austin-Zimmerman I, Spinazzola E, Quattrone D, Wu-Choi B, Trotta G, Li Z, Johnson E, Richards AL, Freeman TP, Tripoli G, Gayer-Anderson C, Rodriguez V, Jongsma HE, Ferraro L, La Cascia C, Tosato S, Tarricone I, Berardi D, Bonora E, Seri M, D'Andrea G, Szöke A, Arango C, Bobes J, Sanjuán J, Santos JL, Arrojo M, Velthorst E, Bernardo M, Del-Ben CM, Rossi Menezes P, Selten JP, Jones PB, Kirkbride JB, Rutten BPF, Tortelli A, Llorca PM, de Haan L, Stilo S, La Barbera D, Lasalvia A, Schurnhoff F, Pignon B, van Os J, Lynskey M, Morgan C; EU-GEI WP2 Group; O' Donovan M, Lewis CM, Sham PC, Murray RM, Vassos E, Di Forti M. Austin-Zimmerman I, et al. Among authors: szoke a. Psychol Med. 2024 Dec 6;54(15):1-13. doi: 10.1017/S0033291724002058. Online ahead of print. Psychol Med. 2024. PMID: 39637925 Free PMC article.
239 results